Stakeholder attitudes and needs regarding cell-free fetal DNA testing

Current Opinion in Obstetrics and Gynecology

Volumn 28, Issue 2, 2016, Pages 125-131

  Hill, Melissa ^a,b   Lewis, Celine ^a,b   Chitty, Lyn S ^a,b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cell free fetal DNA; counseling; noninvasive prenatal testing and diagnosis; stakeholder viewpoints

Indexed keywords

CELL FREE SYSTEM; CLINICAL PRACTICE; DECISION MAKING; DNA DETERMINATION; GENETIC COUNSELING; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMED CONSENT; PARENT COUNSELING; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SEX CHROMOSOME ABERRATION; SPONTANEOUS ABORTION; ATTITUDE TO HEALTH; BLOOD; COUNSELING; DOCTOR PATIENT RELATION; FEMALE; GENETIC SCREENING; PARENT; PROCEDURES;

DNA;

ATTITUDE TO HEALTH; COUNSELING; DECISION MAKING; DELIVERY OF HEALTH CARE; DNA, NEOPLASM; FEMALE; GENETIC TESTING; HUMANS; PARENTS; PHYSICIAN-PATIENT RELATIONS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84960357360     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000251     Document Type: Review

References (61)

1. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350:485-487.
2. Twiss P, Hill M, Daley R, Chitty LS. Noninvasive prenatal testing for Down syndrome. Semin Fetal Neonatal Med 2014; 19:9-14.
3. Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. Prenat Diagn 2015; 35:959-967.
4. Hayden EC. Prenatal-screening companies expand scope of DNA tests. Nature 2014; 507:19.
5. Kooij L, Tymstra T, Berg P, et al. The attitude of women toward current and future possibilities of diagnostic testing in maternal blood using fetal DNA. Prenat Diagn 2009; 29:164-168.
6. Tischler R, Hudgins L, Blumenfeld YJ, et al. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn 2011; 31:1292-1299.
7. Kelly SE, Farrimond HR. Noninvasive prenatal genetic testing: a study of public attitudes. Public Health Genomics 2012; 15:73-81.
8. Lewis C, Silcock C, Chitty LS. Noninvasive prenatal testing for Down's syndrome: pregnant women's views and likely uptake. Public Health Genomics 2013; 16:223-232.
9. Kellogg G, Slattery L, Hudgins L, Ormond K. Attitudes of mothers of children with Down syndrome towards noninvasive prenatal testing. J Genet Couns 2014; 23:805-813.
10. Allyse M, Sayres LC, Goodspeed TA, Cho MK. Attitudes towards noninvasive prenatal testing for aneuploidy among US adults of reproductive age. J Perinatol 2014; 34:429-434.
11. Farrell RM, Agatisa PK, Nutter B. What women want: lead considerations for current and future applications of noninvasive prenatal testing in prenatal care. Birth 2014; 41:276-282.
12. Lewis C, Hill M, Silcock C, et al. Noninvasive prenatal testing for trisomy 21: a cross-sectional survey of service users' views and likely uptake. BJOG 2014; 121:582-594.
13. van Schendel RV, Kleinveld JH, Dondorp WJ, et al. Attitudes of pregnant women and male partners towards noninvasive prenatal testing and widening the scope of prenatal screening. Eur J Hum Genet 2014; 22:1345-1350.
14. van Schendel RV, Dondorp WJ, Timmermans DR, et al. NIPT-based screening for Down syndrome and beyond: what do pregnant women think? Prenat Diagn 2015; 35:598-604.
15. Farrimond HR, Kelly SE. Public viewpoints on new noninvasive prenatal genetic tests. Public Underst Sci 2013; 22:730-744.
16. Yi H, Hallowell N, Griffiths S, Yeung Leung T. Motivations for undertaking DNA sequencing-based noninvasive prenatal testing for fetal aneuploidy: a qualitative study with early adopter patients in Hong Kong. PLoS One 2013; 8:e81794.
17. Horsting JM, Dlouhy SR, Hanson K, et al. Genetic counselors' experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy. J Genet Couns 2014; 23:377-400.
18. Buchanan A, Sachs A, Toler T, Tsipis J. NIPT: current utilization and implications for the future of prenatal genetic counseling. Prenat Diagn 2014; 34:850-857.
19. Lewis C, Hill M, Skirton H, Chitty LS. Development and validation of a measure of informed choice for women undergoing noninvasive prenatal testing for aneuploidy. Eur J Hum Genet 2015. [Epub ahead of print]
20. Farrell R, Hawkins A, Barragan D, et al. Knowledge, understanding, and uptake of noninvasive prenatal testing among Latina women. Prenat Diagn 2015; 35:748-753.
21. Lewis C, Hill M, Skirton H, Chitty LS. Fetal sex determination using cell-free fetal DNA: service users' experiences of and preferences for service delivery. Prenat Diagn 2012; 32:735-741.
22. Lewis C, Hill M, Skirton H, Chitty LS. Noninvasive prenatal diagnosis for fetal sex determination: benefits and disadvantages from the service users' perspective. Eur J Hum Genet 2012; 20:1127-1133.
23. Hill M, Compton C, Lewis C, et al. Determination of foetal sex in pregnancies at risk of haemophilia: a qualitative study exploring the clinical practices and attitudes of health professionals in the United Kingdom. Haemophilia 2011; 18:575-583.
24. Alexander E, Kelly S, Kerzin-Storrar L. Noninvasive prenatal testing: UK genetic counselors' experiences and perspectives. J Genet Couns 2015; 24:300-311.
25. Lewis C, Hill M, Chitty LS. Noninvasive prenatal diagnosis for single gene disorders: experience of patients. Clin Genet 2014; 85:336-342.
26. Hill M, Compton C, Karunaratna M, et al. Client views and attitudes to noninvasive prenatal diagnosis for sickle cell disease, thalassaemia and cystic fibrosis. J Genet Couns 2014; 23:1012-1021.
27. Hill M, Karunaratna M, Lewis C, et al. Views and preferences for the implementation of noninvasive prenatal diagnosis for single gene disorders from health professionals in the United Kingdom. Am J Med Genet A 2013; 161A:1612-1618.
28. Hill M, Suri R, Nash E, et al. Preferences for prenatal tests for cystic fibrosis: a discrete choice experiment to compare the views of adult patients, carriers of cystic fibrosis and health professionals. J Clin Med 2014; 3:176-190.
29. Skirton H, Goldsmith L, Chitty LS. An easy test but a hard decision: ethical issues concerning noninvasive prenatal testing for autosomal recessive disorders. Eur J Hum Genet 2015; 23:1004-1009.
30. Oxenford K, Silcock C, Hill M, Chitty L. Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women. Prenat Diagn 2013; 33:688-694.
31. Skirton H, Goldsmith L, Jackson L, et al. Offering prenatal diagnostic tests: European guidelines for clinical practice. Eur J Hum Genet 2014; 22:580-586.
32. Sachs A, Blanchard L, Buchanan A, et al. Recommended pretest counseling points for noninvasive prenatal testing using cell-free DNA: a 2015 perspective. Prenat Diagn 2015; 35:968-971.
33. Allyse M, Sayres LC, Goodspeed T, et al. 'Don't want no risk and don't want no problems': public understandings of the risks and benefits of noninvasive prenatal testing in the United States. AJOB Empir Bioeth 2015; 6:5-20.
34. Michie S, Dormandy E, Marteau TM. The multidimensional measure of informed choice: a validation study. Patient Educ Couns 2002; 48: 87-91.
35. van den Berg M, Timmermans DR, Ten Kate LP, et al. Are pregnant women making informed choices about prenatal screening? Genet Med 2005; 7:332-338.
36. Hill M, Fisher J, Chitty LS, Morris S. Women's and health professionals' preferences for prenatal tests for Down syndrome: a discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests. Genet Med 2012; 14:905-913.
37. Beulen L, Grutters JP, Faas BH, et al. Women's and healthcare professionals' preferences for prenatal testing: a discrete choice experiment. Prenat Diagn 2015; 35:549-557.
38. Hill M, Johnson J, Langlois S, et al. Preferences for prenatal tests for Down syndrome: an international comparison of the views of pregnant women and health professionals. Eur J Hum Genet 2015. [Epub ahead of print]
39. van den Heuvel A, Chitty L, Dormandy E, et al. Is informed choice in prenatal testing universally valued? A population-based survey in Europe and Asia. BJOG 2009; 116:880-885.
40. Silcock C, Liao LM, Hill M, Chitty LS. Will the introduction of noninvasive prenatal testing for Down's syndrome undermine informed choice? Health Expect 2015; 18:1658-1671.
41. Mozersky J. Hoping someday never comes: deferring ethical thinking about noninvasive prenatal testing. AJOB Empir Bioeth 2015; 6:31-41.
42. Fisher J. First-trimester screening: dealing with the fall-out. Prenat Diagn 2011; 31:46-49.
43. Fisher J. Supporting parents after disclosure of abnormal first trimester screening results. Curr Opin Obstet Gynecol 2012; 24:109-113.
44. Kou KO, Poon CF, Tse WC, et al. Knowledge and future preference of Chinese women in a major public hospital in Hong Kong after undergoing noninvasive prenatal testing for positive aneuploidy screening: a questionnaire survey. BMC Pregnancy Childbirth 2015; 15:199.
45. Hodgson J, Spriggs M. A practical account of autonomy: why genetic counseling is especially well suited to the facilitation of informed autonomous decision making. J Genet Couns 2005; 14:89-97.
46. Farrell R, Agatisa PK, Mercer B, et al. Balancing risks: the core of women's decisions about noninvasive prenatal testing. AJOB Empir Bioeth 2015; 6:42-53.
47. Chitty LS, Wright D, Verhoef TI, et al. A prospective cohort study and economic model to evaluate costs and benefits, acceptability and implications at a population level of implementing noninvasive prenatal testing for aneuploidy into routine NHS maternity care. 2015; Manuscript under review.
48. Lau TK, Chan MK, Salome Lo PS, et al. Noninvasive prenatal screening of fetal sex chromosomal abnormalities: perspective of pregnant women. J Matern Fetal Neonatal Med 2012; 25:2616-2619.
49. Agatisa PK, Mercer MB, Leek AC, et al. A first look at women's perspectives on noninvasive prenatal testing to detect sex chromosome aneuploidies and microdeletion syndromes. Prenat Diagn 2015; 35:692-698.
50. Yotsumoto J, Sekizawa A, Koide K, et al. Attitudes toward noninvasive prenatal diagnosis among pregnant women and health professionals in Japan. Prenat Diagn 2012; 32:674-679.
51. Dondorp W, de Wert G, Bombard Y, et al. Noninvasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015; 23:1592.
52. Royal College of Obstetricians and Gynaecologists. Noninvasive prenatal testing for chromosomal abnormality using maternal plasma DNA (Scientific Impact Paper No. 15). 2014. http://wwwrcogorguk/noninvasive-prenantaldiagnosis-using-cell-free-dna-maternal-blood. [Accessed September 2015]
53. American College of Obstetricians, Gynecologists. Committee Opinion No. 640: Cell-free DNA Screening for Fetal Aneuploidy. Obstet Gynecol 2015; 126:e31-e37.
54. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013; 15:395-398.
55. Wilson KL, Czerwinski JL, Hoskovec JM, et al. NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. J Genet Couns 2013; 22:4-15.
56. Position statement from the Italian College of Fetal Maternal Medicine: noninvasive prenatal testing (NIPT) by maternal plasma DNA sequencing. J Prenat Med 2013; 7:19-20.
57. Haymon L, Simi E, Moyer K, et al. Clinical implementation of noninvasive prenatal testing among maternal fetal medicine specialists. Prenat Diagn 2014; 34:416-423.
58. Lewis C, Choudhury M, Chitty LS. 'Hope for safe prenatal gene tests'. A content analysis of how the UK press media are reporting advances in noninvasive prenatal testing. Prenat Diagn 2015; 35:420-427.
59. Truitt AR, Nguyen MHV. Printing unrealistic expectations: a closer look at newspaper representations of noninvasive prenatal testing. AJOB Empir Bioeth 2015; 6:68-80.
60. Skirton H, Goldsmith L, Jackson L, et al. Noninvasive prenatal testing for aneuploidy: a systematic review of Internet advertising to potential users by commercial companies and private health providers. Prenat Diagn 2015; 35:1167-1175.
61. Kloza EM, Haddow PK, Halliday JV, et al. Evaluation of patient education materials: the example of circulating cell free DNA testing for aneuploidy. J Genet Couns 2015; 24:259-266.